Citius Oncology, Inc. Common Stock
CTORStock
$0.68−66.49%52W
Market Cap$60.44M
P/E—
Div yield—
Beta3.42
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-54.51%
Price vs S&P 500 (4W)-4.04%
VGM Score25.89
Market Capitalization$60.44M
Earnings Surprise History
Q2 26-0.27est. -0.01
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTORCitius Oncology, Inc. Common Stock | — | — | D | $0.68 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Citius Oncology is a biopharmaceutical company developing targeted cancer therapies through lower-risk approaches, including new formulations and expanded indications for approved drugs. The company leverages intellectual property and regulatory exclusivity to accelerate market entry while serving key cancer centers.